The global sales of sexually transmitted diseases diagnostics are estimated to be worth USD 4,431.4 million in 2024 and are anticipated to reach a value of USD 8,964.7 million by 2034. Sales are projected to rise at a CAGR of 7.3% over the forecast period between 2024 and 2034. The revenue generated by sexually transmitted diseases diagnostics in 2023 was USD 4,129.9 million. The industry is anticipated to exhibit a Y-o-Y growth of 7.5% in 2024.
The number of people suffering from sexually transmitted diseases (STDs) has increased exponentially over the past decade. As the incidence of sexually transmitted diseases such as herpes simplex virus (HSV), HIV (human immunodeficiency virus), etc. increases, countries across the globe employs national screening programs to increase the uptake of sexually transmitted diseases diagnostics coverage.
Government agencies are encouraging people to follow strict preventive measures to mitigate the sexually transmitted infections rate.
Moreover, the government and other non-government organizations have launched various reimbursement policies where they offer reimbursement for the diagnosis and treatment of sexually transmitted diseases. These factors are significantly boosting the demand for sexually transmitted disease diagnostics solutions.
Global Sexually Transmitted Diseases Diagnostics Industry Assessment
| Attributes | Key Insights |
|---|---|
| Historical Size, 2023 | USD 4,129.9 million |
| Estimated Size, 2024 | USD 4,431.4 million |
| Projected Size, 2034 | USD 8,964.7 million |
| Value-based CAGR (2024 to 2034) | 7.3% |
As the awareness regarding various sexually transmitted diseases increases, the demand for diagnostics measures for sexually transmitted diseases among people also increases. The demand arises from various factors such as technological advancement that has made it easier for people to access information about it, increasing knowledge regarding the prevalence rates associated with the infections as well as enhanced medical care.
Based on location, the laboratory segment is expected to be a dominating segment in the global sexually transmitted diseases diagnostics market in the year 2024, which is projected to contribute 63.7% of the revenue share.
In addition to the increased awareness regarding sexually transmitted diseases, the rising number of people suffering from various sexually transmitted diseases is also expected to augment the industry growth.
For instance, on May 21, 2024, the World Health Organization (WHO) provided the data regarding the prevalence of STIs which suggest that more than 1 million curable sexually transmitted diseases are acquired every day by people across the globe.
Moreover, according to the same source as above, in 2020, there were around 374 million new cases of sexually transmitted infection in people 15 to 49 years across the globe. Out of these 374 million new cases, every 1 of 4 STIs was curable. Similarly, in the year 2022, around 500 million people worldwide had genital herpes simplex virus infection (HSV or herpes)
As the prevalence of sexually transmitted diseases is rising, there is shift from old conventional method for disease diagnosis to more modern and faster molecular diagnostics one. Key manufacturers are also investing heavily in to their R&D so that they can develop modern diagnostics method for communicable diseases.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The table below compares the compound annual growth rate (CAGR) for the global sexually transmitted diseases diagnostics market from 2023 to 2024 during the first half of the year. This overview highlights key changes and trends in revenue growth, offering valuable insights into market dynamics.
H1 covers January to June, while H2 spans July to December. In the first half (H1) of the decade from 2023 to 2033, the business is predicted to surge at a CAGR of 8.3%, followed by a slightly lower growth rate of 7.7% in the second half (H2) of the same decade.
| Particular | Value CAGR |
|---|---|
| H1 | 8.3% (2023 to 2033) |
| H2 | 7.7% (2023 to 2033) |
| H1 | 7.3% (2024 to 2034) |
| H2 | 7.0% (2024 to 2034) |
Moving into the subsequent period, from H1 2024 to H2 2034, the CAGR is projected to decrease slightly to 7.3% in the first half and remain relatively moderate at 7.0% in the second half. In the first half (H1) the market witnessed a decrease of 100 BPS while in the second half (H2), the market witnessed a decrease of 70 BPS.
Increasing Prevalence of Sexually Transmitted Diseases Driving Market Growth
The sexually transmitted diseases are caused by sexually transmitted infections. These diseases are assumed to be spread mainly by sexual contact. However, a person can get infected by these diseases via contact with infected blood, semen, saliva, or other body fluids.
Sexually transmitted diseases can also be spread in ways other than sexual contact. For example, a mother can transmit the infection to her baby during pregnancy or it can also spread by using the same needle on different patients.
As the prevalence of sexually transmitted diseases increases the demand for its effective diagnostics method also increases. This will eventually drive the industry growth over the forecast period.
For instance, according to the government of UK there were around 401,800 of cases of STIs in UK in 2023 which indicated an increase of 4.7% from 2022 which was 383,789. Out of which the cases of chlamydia was highest and accounted for around 194,970 of cases out of the total number of cases, while gonorrhea cases were 2nd with 85,223 number of cases in UK in 2023.
Such high prevalence of sexually transmitted diseases will persuade healthcare organization and government to invest more in enhanced screening programs and public health campaigns.
Emergence of Multiplex Pathogen Testing Opens a New Window of Opportunity
Multiplex testing can be used to detect the presence of multiple pathogens related to sexually transmitted diseases from a single sample. This method is extremely helpful in individuals who have symptoms of STDs and who may have co-infections where more than one infection is present at the same time.
The major benefit of multiplex tests is the efficiency associated with them. These tests reduce the time and resources required in the diagnosis of a multiple set of infections and hence are quick and fast. For example, a single test can be used to screen for various STDs such as chlamydia, gonorrhea, syphilis and others.
This is helpful in clinical practice where timely diagnosis is necessary to prevent further spreading of disease. Moreover, multiplex testing nowadays is combined with point-of-care diagnostics, which has increased its reach in developed as well as rural areas. Moreover, key manufacturer have adopted the multiplex diseases diagnostics and are focused on launching new product, which gives them competitive edge.
For instance, in May 2022, Abbott, a USA-based multinational pharmaceutical company, announced that they have received USA FDA clearance for its Alinity™ m STI Assay. This new test kits can be used for detection of four common sexually transmitted infections (STIs) namely Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), Trichomonas vaginalis (TV), and Mycoplasma genitalium (MG) with a single swab sample.
Growing Demand for Point-Of-Care Testing
Point-of-care (POC) testing enables medical professionals to diagnose and provide suitable treatments to individuals infected with sexually transmitted diseases such as HIV and others. This has led to better patient recovery, lowered mortality rates, and reduced rates of diseases transfer.
This approach facilitates the use of point-of-care tests such as lateral flow assays or dipsticks in private environments for detecting STIs because they are highly sensitive and specific. Such procedures are often preferred in a homecare setting due its simplicity.
Point-of-care (POC) testing offers quick results that allow healthcare providers to diagnose and treat STDs without necessarily involving hospitalization or the use of lab tests. This approach is also a cheaper way of reducing repeated visits to health practitioners as well as improving clinical workflows.
Innovation within this sector has been spurred by introduction of novel POC technologies like smartphones based devices which are still able to provide information through wearable sensors.
Thus, Point-of-care (POC) testing will be a major trend of this industry due to its ability to deliver rapid, accurate results in non-laboratory settings. Moreover, POCT offers fast, rapid test results and enables immediate treatment decisions, and reduces the burden on traditional healthcare systems, driving its adoption in both developed and developing regions.
High costs of diagnostic tests may Restrict Sexually Transmitted Diseases Diagnostics Market Growth
The prevalence of sexually transmitted diseases is high. This makes it necessary for people to adopt various diagnostics measures. However, the cost of such devices and tests are quite high. This high price can limit the adoption of such STIs diagnostics solution in growing economies such as South Korea, India, Brazil and especially in South Africa.
This can act as an anchor to the market growth. Moreover, other challenges such as training costs and annual maintenance cost can also limit their adoption. Moreover, the overall cost further increases as these devices and instrument requires regular maintenance and calibration to maintain their accuracy. In addition, the expense of teaching caregivers on how to operate these devices can also be huge.
For instance, TrueMark™ STI Select Panel, a STD test kits manufactured by Thermo Fisher Scientific Inc., which a global medical devices manufacturer, cost around USD 1,500 for a single kit.
Moreover, the cost of maintaining these testing facilities is also high. Thus, even though the need for proper and effective STD testing is high. The cost of such testing will limit its adoption due to the concerns of affordability.
Principal Consultant
The global sexually transmitted diseases diagnostics industry recorded a CAGR of 6.9% during the historical period between 2019 and 2023. The growth of Sexually transmitted diseases diagnostics industry was positive as it reached a value of USD 8,964.7 million in 2034 from USD 4,431.4 million in 2024.
The market for sexually transmitted diseases diagnostics is anticipated to grow positively in the near future due to the rise in number people suffering from sexually transmitted diseases. The requirement for better sexually transmitted disease diagnostics technologies will rise as the prevalence of HIV, gonorrhea, syphilis and other increases.
Key players are focused on new products launch so as to provide proper diagnosis of these disease. This will also have a positive impact on the market. For instance, in November 2023, LetsGetChecked Inc. a USA-based home healthcare company, announced that their Simple 2 Test have received marketing authorization from the USA Food and Drug Administration. This test is home based test for diagnosis of chlamydia and gonorrhea
The Covid-19 pandemic had a negative impact on this industry and led to a temporary slowing down of this market in 2020. This was because different categories of businesses were forced to close down by the lockdown imposed by several government authority during the pandemic. However, post pandemic the market experienced a gradual growth.
In addition, there are several other factors which will increase the market growth such as increasing research & development activities by key market players, rising technological advancement, increasing use of novel biomarker for diagnostics purpose and others. Government organization are also involved in promoting research & development for early diagnosis of sexually transmitted diseases by proving research grant and funding to various universities and manufacturers.
Tier 1 companies are the major companies as they hold a 29.6% share worldwide. These companies have generated revenue over USD 100 million. These companies have large product portfolio and a high production capacity. These industry leaders stand out for having a wide geographic reach. The companies within tier 1 have a good reputation and high brand value.
These companies frequently get involved in strategies such as acquisition and product launches. Prominent companies within tier 1 include Abbott, Thermo Fisher Scientific Inc., CERTEST BIOTEC, OPERON, F. Hoffmann-La Roche Ltd, and Bio-Rad laboratories
Tier 2 companies are relatively smaller as compared with tier 1 players. The tier 2 companies hold a share of 36.5% worldwide. These firms may not have cutting-edge technology or a broad global reach, but they do ensure regulatory compliance and have good technology.
The players are more competitive when it comes to pricing and target niche markets. Key Companies under this category include Qaigen Inc., Diasorin SPA, MedMira Inc., Hologic, and others
Compared to Tiers 1 and 2, Tier 3 companies offer sexually transmitted diseases diagnostics, but with smaller revenue spouts and less influence. These companies mostly operate in one or two countries and have limited customer base.
Tier 3 companies, although, smaller but are essential for the market. The companies such as Cepheid, BioMeriuex and other falls under this category. They specialize in specific products and cater to niche markets, adding diversity to the industry.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The section below covers the industry analysis for the sexually transmitted diseases diagnostics market for different countries. Market demand analysis on key countries in several regions of the globe, including North America, Asia Pacific, Europe, and others, is provided.
The United States is anticipated to remain at the forefront in North America, with a value share of 81.6% through 2034. In Asia Pacific, India is projected to witness a CAGR of 6.9% by 2034.
| Countries | Value CAGR (2024 to 2034) |
|---|---|
| USA | 3.4% |
| Germany | 1.9% |
| France | 3.1% |
| UK | 2.2% |
| China | 6.1% |
| India | 6.9% |
| South Korea | 4.8% |
Germany’s sexually transmitted diseases diagnostics market is poised to exhibit a CAGR of 1.9% between 2024 and 2034. The Germany holds highest market share in European market.
Germany, the prevalence of sexually transmitted diseases is constantly rising. The rising prevalence of STD such as HIV, Chlamydia and other STDs in Germany will boost the need for its proper and effective diagnosis.
This will lead to increased usage of sexually transmitted diseases diagnostics devices and kits in Germany. Moreover, as the people are getting more aware regrading theses STDs they are seeking its diagnostics and treatment measures. This is driving the growth of the chlamydia diagnostics market in Germany.
The increasing healthcare expenditure in Europe is leading to more investments in healthcare infrastructure, including diagnostic facilities. This is driving the growth of the chlamydia diagnostics market as more individuals have access to testing and treatment.
USA market is anticipated to grow at a CAGR of 3.4% throughout the forecast period.
The United States is the largest market for sexually transmitted diseases diagnosis in North America. Availability of larger number of players, better healthcare infrastructure, awareness regarding diagnostics measures and technological advancement are the factor driving the growth in USA In addition, in this country healthcare spending is high and test for STIs are easily available.
The government initiative such as to promote early disease diagnosis also increases the demand for sexually transmitted diseases diagnostics kits and devices. Heightened public awareness and government initiatives aimed at promoting regular STD testing are also contributing to the market expansion.
In the United States there are large number of global manufacturer of sexually transmitted diseases diagnostics solution which makes such kinds of diagnostics test easily accessible.
Improvements in diagnostic technologies, including rapid point-of-care testing and nucleic acid amplification tests, make STD diagnostics more accessible, efficient, and accurate which further supports growth in demand. The solid infrastructure of the USA healthcare system, combined with large investments in healthcare services, allows for pervasive adoption of improved diagnostic tools.
In terms of industrial growth and infrastructure development, China is anticipated to be a strong contender, most importantly in the year 2023. The country is projected to grow at a CAGR of 6.1% between 2024 and 2034
As the prevalence of STDs and its awareness increases the Sexually transmitted diseases (STDs) diagnostics in China are expected to experience growth. The rise in STD cases will increase demand for effective diagnostic solutions among the younger demographic groups in China.
In addition, government public health campaigns and increased accessibility to health promotion and healthcare services also increases the awareness and accessibility to such diagnostics tools. Moreover, healthcare infrastructure in China and diagnostics technologies have increased rapidly, including the power of rapid point-of-care testing and nucleic acid amplification tests which has made STD diagnostics both accessible and efficient.
Apart from this, with the growing trend toward early detection and prevention, and increasing investments in healthcare, the demand for STD diagnoses in China would rise.
The section contains information about the leading segments in the industry. Based on location, the laboratory segment is expected to account 63.7% of the global share in 2024.
| Location | Laboratory |
|---|---|
| Value Share (2024) | 63.7% |
The laboratory segment is projected to dominate the industry in terms of revenue, accounting for almost 63.7% of the share in 2024. The sexually transmitted diseases diagnostics are mostly done in a laboratory. This decreases the risk of false positive and false negative results.
Owing to such high usage of these techniques in laboratory, this segment will hold dominant position. High sensitivity and specificity of laboratory-based diagnostics test like Nucleic Acid Amplification Tests (NAATs) for the detection of infections such as chlamydia, gonorrhea, or syphilis make them a gold standard for diagnosis of diseases.
The laboratories are well-equipped with the potential to process a huge volume of samples, which forms the basis for screening and confirming diagnosis among symptomatic and asymptomatic patients.
However, point of care testing will have a higher growth rate, as point of care testing offers several advantages such as they can be performed in patient’s comfort, they are generally fast and quick and are also cost effect. These advantages make point of care preferred choice for patients.
| Device | Laboratory Devices |
|---|---|
| Value Share (2024) | 67.6% |
By device, the laboratory devices segment is expected to hold a share of 67.6% in 2024. As most of sexually transmitted diseases diagnosis is done either in hospitals, clinic or diagnostics lab, the usage of such test is higher in healthcare facilities. Owing to such high usage of STD diagnostics in labs, the laboratory devices is expected to hold dominant position in the device type segment.
Laboratory devices such as advanced analyzers, automated systems, and PCR machines, are irreplaceable in running high-throughput, highly sensitive diagnostic tests-for example, nucleic acid amplification tests and enzyme-linked immunosorbent assays. Moreover, these instrument are heavy and bulky and requires large storage space. So they mostly used in hospitals or diagnostics lab.
Moreover, these instrument requires frequent calibration so as to avoid false positive and false negative results. These instruments and devices also require skilled technician for its proper operation. Thus, the laboratory devices would hold major hare.
There are many key player in this industry. In addition, there are many small and regional players as well. These manufacturers are focused on constantly innovating and improving their product portfolio
Prominent producers of sexually transmitted diseases diagnostics products are concentrating on growing internationally in order to increase their revenue and increase the size of their sales footprint in developing nations through the acquisition of regional competitors. The key strategies adopted by manufacturers are agreements, product launches, sponsoring research, and strategic collaborations.
Recent Industry Developments in Sexually Transmitted Diseases Diagnostics Market
In terms of diagnostic test, the industry is divided into cultural/isolated organisms, molecular test, immunology assay, and other types of testing.
In terms of device, the industry is segregated into laboratory devices and point of sales
In terms of disease, the industry is divided into Gonorrhea, syphilis, chlamydia, herpes simplex virus, human papillomavirus and others.
In terms of location, the industry is segregated into laboratory and point of care
In terms of end user, the industry is segregated into hospitals, clinics, diagnostics labs, homecare setting and other
Key countries of North America, Latin America, Europe, East Asia, South Asia & Pacific, Middle East and Africa (MEA) have been covered in the report.
The global sexually transmitted diseases diagnostics industry is projected to witness CAGR of 7.3% between 2024 and 2034.
The global sexually transmitted diseases diagnostics industry stood at USD 4,129.9 million in 2023.
The global sexually transmitted diseases diagnostics industry is anticipated to reach USD 8,964.7 million by 2034 end.
China is expected to show a CAGR of 6.1% in the assessment period.
The key players operating in the global sexually transmitted diseases diagnostics industry include Thermo Fisher Scientific Inc., CERTEST BIOTEC, OPERON, F. Hoffmann-La Roche Ltd, Bio-Rad laboratories, Qaigen Inc., Diasorin SPA, MedMira Inc., Hologic, Cepheid and BioMeriuex.
1. Executive Summary 2. Industry Introduction, including Taxonomy and Market Definition 3. Market Trends and Success Factors, including Macro-economic Factors, Market Dynamics, and Recent Industry Developments 4. Global Market Demand Analysis, 2019 to 2023 and Forecast 2024 to 2034, including Historical Analysis, and Future Projections 5. Global Market Analysis, 2019 to 2023 and Forecast 2024 to 2034 5.1. By Diagnostic Test 5.2. By Device 5.3. By Disease 5.4. By Location 5.5. By End User 5.6. By Region 6. Global Market Analysis, 2019 to 2023 and Forecast 2024 to 2034, by Diagnostic Test 6.1. Cultural/Isolated Organisms 6.2. Molecular Test 6.3. Immunology Assay 6.4. Other types of testing 7. Global Market Analysis, 2019 to 2023 and Forecast 2024 to 2034, By Device 7.1. Laboratory Devices 7.1.1. Thermal Cyclers-PCR 7.1.2. Lateral Flow Readers Immunochromatographic Assay Flow Cytometers 7.1.3. Absorbance Microplate Readers Enzyme-Linked Immunosorbent Assay 7.1.4. Others 7.2. Point of Sales 7.2.1. Phone Chips 7.2.2. Portable/Bench 7.2.3. Diagnostic Kits 8. Global Market Analysis, 2019 to 2023 and Forecast 2024 to 2034, By Disease 8.1. Gonorrhea 8.2. Syphilis 8.3. Chlamydia 8.4. Herpes simplex virus 8.5. Human papillomavirus 8.6. Others 9. Global Market Analysis, 2019 to 2023 and Forecast 2024 to 2034, by Location 9.1. Laboratory 9.2. Point of Care 10. Global Market Analysis, 2019 to 2023 and Forecast 2024 to 2034, by End User 10.1. Hospitals 10.2. Clinics 10.3. Diagnostics Labs 10.4. Homecare Setting 10.5. Other 11. Global Market Analysis, 2019 to 2023 and Forecast 2024 to 2034, by Region 11.1. North America 11.2. Latin America 11.3. East Asia 11.4. South Asia and Pacific 11.5. Western Europe 11.6. Eastern Europe 11.7. Middle East and Africa 12. North America Sales Analysis, 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 13. Latin America Sales Analysis, 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 14. East Asia Sales Analysis, 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 15. South Asia & Pacific Sales Analysis, 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 16. Western Europe Sales Analysis, 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 17. Eastern Europe Sales Analysis, 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 18. Middle East and Africa Sales Analysis, 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 19. Sales Forecast 2024 to 2034 by Diagnostic Test and End User for 30 Countries 20. Competition Outlook, including Market Structure Analysis, Company Share Analysis, by Key Players, and Competition Dashboard 21. Company Profile 21.1. Abbott 21.2. Thermo Fisher Scientific Inc. 21.3. CERTEST BIOTEC 21.4. OPERON 21.5. F. Hoffmann-La Roche Ltd 21.6. Bio-Rad laboratories 21.7. Qaigen Inc. 21.8. Diasorin SPA 21.9. MedMira Inc. 21.10. Hologic 21.11. Cepheid 21.12. BioMeriuex
Explore Healthcare Insights
View Reports
Sexually Transmitted Diseases Diagnostics Market
